(Q37682245)

22 August 2017

Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis (English)

1 reference

22 August 2017

0 references

William F Pendergraft

1

1 reference

22 August 2017

Frank B Cortazar

2

1 reference

22 August 2017

Julia Wenger

3

1 reference

22 August 2017

Andrew P Murphy

4

1 reference

22 August 2017

Eugene P Rhee

5

1 reference

22 August 2017

Karen A Laliberte

6

1 reference

22 August 2017

John L Niles

7

1 reference

22 August 2017

language of work or name

1 reference

13 March 2014

1 reference

Clinical Journal of the American Society of Nephrology

22 August 2017

1 reference

22 August 2017

9

1 reference

22 August 2017

4

1 reference

22 August 2017

736-744

1 reference

Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Genetically distinct subsets within ANCA-associated vasculitis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Progress in treatment of ANCA-associated vasculitis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Late‐onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Comparing Survival of a Sample to That of a Standard Population

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

B-cell depleting agents for ANCA vasculitides: a new therapeutic approach

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Regulatory B cells in ANCA-associated vasculitis.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Complications of long-term therapy for ANCA-associated systemic vasculitis

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3974359

A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)

1 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24626432

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2215/CJN.07340713

1 reference

22 August 2017

1 reference

22 August 2017

PubMed publication ID

24626432

1 reference